search
Back to results

Immunomodulation With Eltrombopag in ITP (iROM2)

Primary Purpose

Primary Immune Thrombocytopenia (ITP)

Status
Recruiting
Phase
Phase 2
Locations
Switzerland
Study Type
Interventional
Intervention
Eltrombopag (Revolade®)
standard therapy (without eltrombopag): HD-DXM
Sponsored by
University Children's Hospital Basel
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Immune Thrombocytopenia (ITP) focused on measuring eltrombopag, thrombopoietin receptor agonist (TPO-RA), ITP in young and midlife adults

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Informed consent as documented by signature
  • Newly diagnosed primary ITP according to the definition of Rodeghiero et al. and a risk of platelet count of <30x109/l or risk of severe bleeding
  • First-line therapy maximum for 1 week prior to enrolment
  • Bleeding severity and quality of life are neither an inclusion nor an exclusion criterion.

Exclusion Criteria:

  • Patients previously treated for ITP more than 7 days prior to enrolment (e.g. Steroid, intravenous immunoglobulin (IVIG), platelet infusion)
  • Patients treated with second-line drugs prior to enrolment
  • Life-threatening bleeding (and inability to sign informed consent)
  • Secondary ITP
  • Positive family history for ITP
  • Presence or history of autoimmune disease as judged by the investigator
  • Hepatosplenomegaly in the clinical examination
  • Relevant hepatic disease as judged by the investigator
  • Presence or history of thromboembolic disease
  • Patients with splenectomy
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the study
  • Lack of safe double contraception
  • Any vaccination 2 weeks prior start of the study
  • Immunsuppressive and antiplatelet drugs
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, incompetence to judge
  • Participation in another study with investigational drug within the 30 days preceding and during the present study
  • Enrolment of the investigator, his/her family members, employees and other dependent persons

Sites / Locations

  • Aarau Cantonal Hospital, Division of HematologyRecruiting
  • University Children's Hospital Basel (UKBB)Recruiting
  • University Hospital Basel, Division of HematologyRecruiting
  • University Hospital Bern, Division of HematologyRecruiting
  • Liestal Cantonal Hospital, Division of HematologyRecruiting
  • Lucerne Cantonal Hospital, Division of HematologyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Experimental

Arm Label

Standard Arm

Study Arm

Arm Description

HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 1: No planed further treatment. = standard therapy (without eltrombopag)

HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 2: The subjects in the experimental arm will be treated with eltrombopag: Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week (week 21) from day 141-148 with 50 mg every second day. Eltrombopag will be administered on a starting dose of 50mg. After the end of treatment a clinical and laboratory observation follow-up period until week 30 follows.

Outcomes

Primary Outcome Measures

Change in percentual T-regulatory cells (Tregs)
Assessment of the percentage of Tregs (Tregs/CD4) in the study arm compared to the standard arm. The Tregs will be defined as CD4+CD25+ CD127+ in the fluorescence-activated cell sorting (FACS).

Secondary Outcome Measures

Change in Th1/Th2 balance
Change in Th1/Th2 balance will be performed by analysis of immunologic profile (immune cell characteristics, messenger ribonucleic acid (mRNA) of immune cells, cytokines, cytokine concentrations)
Clinical response to eltrombopag therapy
Clinical response to eltrombopag therapy (by assessing need of inpatient daycare and use of rescue treatment)
Platelet response to eltrombopag
Platelet response to eltrombopag: proportion of subjects achieving a platelet count of ≥50x109/l (complete response, response and no response;Response at each assessment is defined as a platelet count of ≥ 50x109/l).

Full Information

First Posted
March 1, 2021
Last Updated
September 5, 2022
Sponsor
University Children's Hospital Basel
Collaborators
Stiftung zur Förderung medizinischer und biologischer Forschung, Novartis Pharmaceuticals, University of Erlangen-Nürnberg, Department of Biology
search

1. Study Identification

Unique Protocol Identification Number
NCT04812483
Brief Title
Immunomodulation With Eltrombopag in ITP
Acronym
iROM2
Official Title
Immunomodulation in Young and Midlife Adults With Newly Diagnosed Primary Immune Thrombocytopenia (ITP): A Randomized Open Label Trial With High-dose Dexamethasone Versus Eltrombopag and High-dose Dexamethasone
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2022 (Actual)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
October 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Children's Hospital Basel
Collaborators
Stiftung zur Förderung medizinischer und biologischer Forschung, Novartis Pharmaceuticals, University of Erlangen-Nürnberg, Department of Biology

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study aims to investigate immunomodulatory effects of eltrombopag combined with dexamethasone in young and midlife adult patients with newly diagnosed primary Immune thrombocytopenia (ITP).
Detailed Description
The randomized open lable study aims to investigate immunomodulatory effects of eltrombopag combined with dexamethasone in young and midlife adult patients with newly diagnosed primary ITP. Treatment protocol will be HD-DXM (40 mg PO, day 1-4) with or without eltrombopag (25-50 mg PO, day 5-140) on an outpatient basis. Immunological investigations will be performed before start of treatment and then on week 3, 20 (end of therapy) and 30. Intervention phase: Medical history and physical examination including assessment of severe bleeding every week until week 4, every second week until week 20. Complete blood count every week until week 10. For the adjustment of the Thrombopoietin receptor agonist (TPO-RA) dose - every second week until week 20. Immunologic panel at the beginning and at week 3 and 20. Follow-up: Three clinical visits are scheduled in the follow-up including a complete blood count: at week 22, 24 and 30. Immunologic panel will be done at week 30 (end of study). High-dose dexamethasone (HD-DXM) will be administered orally (40 mg) from day 1-4, followed by Arm 1 or 2 (1:1 randomization). Arm 1: Standard Arm No planed further treatment. = standard therapy. In case of non-response after 2 courses of HD-DXM (week 4): cross-over to Arm 2: Start Eltrombopag (Revolade®), 50 mg PO until day 140 (details see Arm 2). In case of relapse: repeat HD-DXM (40 mg day 1-4), up to a maximal of 3 courses. Time between 2 courses should be minimal 14 days. In case of re-relapse after the third course: cross-over to Arm 2: Start Eltrombopag (Revolade®), 50 mg PO until day 140 (details see Arm 2). Arm 2: Study Arm Eltrombopag (Revolade®), 50 mg per os, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day. In case of non-response after 4 weeks on eltrombopag: drop out

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Immune Thrombocytopenia (ITP)
Keywords
eltrombopag, thrombopoietin receptor agonist (TPO-RA), ITP in young and midlife adults

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Randomized study evaluating the immunomodulatory effects of eltrombopag versus standard high-dose (HD) DXM therapy (1:1) in newly diagnosed ITP.
Masking
None (Open Label)
Masking Description
The laboratory team will be kept blinded regarding information about response or non-response of patients.
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard Arm
Arm Type
Other
Arm Description
HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 1: No planed further treatment. = standard therapy (without eltrombopag)
Arm Title
Study Arm
Arm Type
Experimental
Arm Description
HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 2: The subjects in the experimental arm will be treated with eltrombopag: Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week (week 21) from day 141-148 with 50 mg every second day. Eltrombopag will be administered on a starting dose of 50mg. After the end of treatment a clinical and laboratory observation follow-up period until week 30 follows.
Intervention Type
Drug
Intervention Name(s)
Eltrombopag (Revolade®)
Intervention Description
Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.
Intervention Type
Drug
Intervention Name(s)
standard therapy (without eltrombopag): HD-DXM
Intervention Description
standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
Primary Outcome Measure Information:
Title
Change in percentual T-regulatory cells (Tregs)
Description
Assessment of the percentage of Tregs (Tregs/CD4) in the study arm compared to the standard arm. The Tregs will be defined as CD4+CD25+ CD127+ in the fluorescence-activated cell sorting (FACS).
Time Frame
before (Tregs/CD4), at week 3 and at the end of the treatment (week 20)
Secondary Outcome Measure Information:
Title
Change in Th1/Th2 balance
Description
Change in Th1/Th2 balance will be performed by analysis of immunologic profile (immune cell characteristics, messenger ribonucleic acid (mRNA) of immune cells, cytokines, cytokine concentrations)
Time Frame
at baseline and weeks 3, 20 and 30
Title
Clinical response to eltrombopag therapy
Description
Clinical response to eltrombopag therapy (by assessing need of inpatient daycare and use of rescue treatment)
Time Frame
trial duration (baseline to week 30)
Title
Platelet response to eltrombopag
Description
Platelet response to eltrombopag: proportion of subjects achieving a platelet count of ≥50x109/l (complete response, response and no response;Response at each assessment is defined as a platelet count of ≥ 50x109/l).
Time Frame
at baseline and weeks 6, 20 and 30
Other Pre-specified Outcome Measures:
Title
Number of Adverse Events
Description
Safety of eltrombopag analyzed by documentation of number of Adverse Events
Time Frame
trial duration (baseline to week 30)
Title
Severe bleeding
Description
Severe bleeding is defined as bleeding requiring hospital admission and/or blood transfusion.
Time Frame
trial duration (baseline to week 30)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Informed consent as documented by signature Newly diagnosed primary ITP according to the definition of Rodeghiero et al. and a risk of platelet count of <30x109/l or risk of severe bleeding First-line therapy maximum for 1 week prior to enrolment Bleeding severity and quality of life are neither an inclusion nor an exclusion criterion. Exclusion Criteria: Patients previously treated for ITP more than 7 days prior to enrolment (e.g. Steroid, intravenous immunoglobulin (IVIG), platelet infusion) Patients treated with second-line drugs prior to enrolment Life-threatening bleeding (and inability to sign informed consent) Secondary ITP Positive family history for ITP Presence or history of autoimmune disease as judged by the investigator Hepatosplenomegaly in the clinical examination Relevant hepatic disease as judged by the investigator Presence or history of thromboembolic disease Patients with splenectomy Women who are pregnant or breast feeding Intention to become pregnant during the course of the study Lack of safe double contraception Any vaccination 2 weeks prior start of the study Immunsuppressive and antiplatelet drugs Known or suspected non-compliance, drug or alcohol abuse Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, incompetence to judge Participation in another study with investigational drug within the 30 days preceding and during the present study Enrolment of the investigator, his/her family members, employees and other dependent persons
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexandra Schifferli, Dr. med.
Phone
+41-61-704-1212
Email
Alexandra.Schifferli@ukbb.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Thomas Kühne, Prof. Dr. med.
Phone
+41-61-704-1212
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexandra Schifferli, Dr. med.
Organizational Affiliation
University Children's Hospital Basel, UKBB
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aarau Cantonal Hospital, Division of Hematology
City
Aarau
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nathan Cantoni, Dr. med.
Facility Name
University Children's Hospital Basel (UKBB)
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandra Schifferli, Dr. med.
Phone
+41-61-704-1212
Email
Alexandra.Schifferli@ukbb.ch
First Name & Middle Initial & Last Name & Degree
Thomas Kühne, Prof. Dr. med.
Phone
+41-61-704-1212
Facility Name
University Hospital Basel, Division of Hematology
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andreas Holbro, PD. Dr. med.
Facility Name
University Hospital Bern, Division of Hematology
City
Bern
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alicia Rovò, PD. Dr. med.
Facility Name
Liestal Cantonal Hospital, Division of Hematology
City
Liestal
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Geneviève Favre, Dr. med.
Facility Name
Lucerne Cantonal Hospital, Division of Hematology
City
Lucerne
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Axel Rüfer, Dr. med.
Phone
+41 41 205 51 47
Email
axel.ruefer@luks.ch

12. IPD Sharing Statement

Learn more about this trial

Immunomodulation With Eltrombopag in ITP

We'll reach out to this number within 24 hrs